SAGA Diagnostics has been accredited to the ISO 17025 standard for its mutation detection laboratory services designed to improve cancer diagnosis, monitoring, and treatment outcomes.
Granted by SWEDAC, the Swedish Board for Accreditation and Conformity Assessment, ISO 17025 is an international quality management standard used to assess the competency of analytical laboratories.
“The entire SAGA team is delighted with achieving this milestone as it demonstrates our commitment to providing the highest quality services and results to our rapidly growing number of customers in the biotechnology, pharmaceutical, academic, and hospital sectors,” says Karolina Holm, Clinical Laboratory QA Manager of SAGA Diagnostics.
SAGA is commercializing ultrasensitive technologies to quantify cancer-associated genetic aberrations in tissue and liquid biopsy samples which are capable of achieving limits of detection down to 0.001% mutant allele fraction, the company states. SAGA’s platform technologies, which are based on digital PCR and next-generation sequencing, are tools to be used in cancer patient stratification, therapy response monitoring, disease relapse identification, as well as in aiding in treatment decisions and as companion diagnostics.
Photo of Lao Saal: SAGA Diagnostics